<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089908</url>
  </required_header>
  <id_info>
    <org_study_id>CIR 199</org_study_id>
    <secondary_id>H.22.04.04.23.B2</secondary_id>
    <nct_id>NCT00089908</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults</brief_title>
  <official_title>Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and&#xD;
      subtropical regions of the world. The purpose of this study is to test the safety of and&#xD;
      immune response to a new dengue virus vaccine in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 2 billion people living in tropical and subtropical regions of the world are at&#xD;
      risk of dengue virus infection. Dengue viruses cause dengue fever, as well as the more severe&#xD;
      dengue hemorrhagic fever/shock syndrome, and dengue virus infection is the leading cause of&#xD;
      hospitalization and death in children in several tropical Asian countries. This study will&#xD;
      evaluate the safety and immunogenicity of a live, attenuated dengue virus called&#xD;
      rDEN1delta30, which is derived from the Western Pacific DEN1 serotype.&#xD;
&#xD;
      This study will last 180 days. Participants in Cohort 1 will be randomly assigned to receive&#xD;
      rDEN1delta30 or placebo at study entry. Cohort 2 will begin only after safety review of all&#xD;
      participants in Cohort 1. Participants in Cohort 2 will receive a higher dose of rDEN1delta30&#xD;
      or placebo.&#xD;
&#xD;
      After vaccination, participants will be asked to monitor their temperature every day for 16&#xD;
      days. Study visits will occur every other day after vaccination until Day 16, followed by 4&#xD;
      additional visits at selected days through Day 180. Blood collection and a targeted physical&#xD;
      exam will occur at each study visit. Some participants will be asked to undergo a skin biopsy&#xD;
      or additional blood collection at selected visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the frequency of vaccine related AEs for each dose graded by severity</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the amount of dengue 1 neutralizing antibody induced by the vaccine</measure>
    <time_frame>At Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the durability of the antibody response</measure>
    <time_frame>At Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the frequency, quantity, and duration of viremia in each dose cohort studied</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the T cell mediated immune response against dengue viruses of those volunteers infected with the rDEN1delta30 vaccine virus with that of uninfected volunteers and placebo recipients</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>If both doses of vaccine are administered, to compare the infectivity rates, safety, and immunogenicity between dose groups</measure>
    <time_frame>At study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One subcutaneous vaccination with placebo into the deltoid region of either arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rDEN1delta30</intervention_name>
    <description>Live attenuated rDEN1delta30 vaccine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for rDEN1delta30</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to be followed for the duration of the study&#xD;
&#xD;
          -  Willing to use acceptable methods of contraception&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic,&#xD;
             autoimmune, or renal disease&#xD;
&#xD;
          -  Behavioral, cognitive, or psychiatric disease that, in the opinion of the&#xD;
             investigator, affects the ability of the volunteer to understand and cooperate with&#xD;
             the study&#xD;
&#xD;
          -  Liver, renal, or hematologic disease&#xD;
&#xD;
          -  Alcohol or drug abuse within 12 months of study entry&#xD;
&#xD;
          -  History of severe allergic reaction or anaphylaxis&#xD;
&#xD;
          -  Emergency room visit or hospitalization for severe asthma within 6 months of study&#xD;
             entry&#xD;
&#xD;
          -  HIV-1 infected&#xD;
&#xD;
          -  HCV infected&#xD;
&#xD;
          -  Hepatitis B surface antigen positive&#xD;
&#xD;
          -  Known immunodeficiency syndrome&#xD;
&#xD;
          -  Use of corticosteroids or immunosuppressive drugs within 30 days of study entry.&#xD;
             Participants who have used topical or nasal corticosteroids are not excluded.&#xD;
&#xD;
          -  Live vaccine within 4 weeks of study entry&#xD;
&#xD;
          -  Killed vaccine within 2 weeks of study entry&#xD;
&#xD;
          -  Blood products within 6 months of study entry&#xD;
&#xD;
          -  Investigational drugs or vaccines within 60 days prior to study entry or while&#xD;
             currently enrolled in this clinical trial&#xD;
&#xD;
          -  Previously received a licensed or experimental yellow fever or dengue vaccine&#xD;
&#xD;
          -  Surgical removal of spleen&#xD;
&#xD;
          -  History of dengue virus infection or other flavivirus infection&#xD;
&#xD;
          -  Other condition that, in the opinion of the investigator, would affect the&#xD;
             participant's participation in the study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Plan to travel to an area where dengue infection is common&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Durbin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Immunization Research, John Hopkins School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Immunization Research, Johns Hopkins School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobs M, Young P. Dengue vaccines: preparing to roll back dengue. Curr Opin Investig Drugs. 2003 Feb;4(2):168-71. Review.</citation>
    <PMID>12669377</PMID>
  </reference>
  <reference>
    <citation>Pang T. Vaccines for the prevention of neglected diseases--dengue fever. Curr Opin Biotechnol. 2003 Jun;14(3):332-6. Review.</citation>
    <PMID>12849789</PMID>
  </reference>
  <reference>
    <citation>Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004 Apr;113(7):946-51. Review.</citation>
    <PMID>15057297</PMID>
  </reference>
  <reference>
    <citation>Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):24-31.</citation>
    <PMID>14740952</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>August 17, 2004</study_first_submitted>
  <study_first_submitted_qc>August 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2004</study_first_posted>
  <last_update_submitted>January 17, 2008</last_update_submitted>
  <last_update_submitted_qc>January 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anna Durbin, MD</name_title>
    <organization>Center for Immunization Research, Johns Hopkins School of Public Health</organization>
  </responsible_party>
  <keyword>Dengue Vaccine</keyword>
  <keyword>Dengue Virus</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>Dengue Shock Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

